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For approximately 2’000 years, thedecoctions of the bark of the Sali-
caceae family have been used to treat
pain, fever, and headaches. It contains
salicin* which probably is the main ac-
tive component ‘per se’, but also is a
pro-drug. Salicin is stable under acidic
conditions and in human saliva; β-glu-
curonidase activity and hydrolysis,
however, convert salicin to saligenin
which is further converted to salicylic
acid in the liver by the cytochrome P-
450 system. Peak plasma concentra-
tion of salicylic acid is found approxi-
mately three hours after oral adminis-
tration of salicin. Other components
are likely to contribute to the anti-in-
flammatory effects of the extract.
Pharmacology and toxicology have
been reviewed in detail elsewhere [1].
A randomised controlled trial (RCT)
compared an extract of white willow to
placebo in patients with chronic back
pain (n=210); it reported that 39% of
the patients were pain-free at a dose of
240 mg salicin vs. 21% pain free ones
with 20 mg salicin and vs. 6% pain free
patients with placebo [2]. Another
study (n=228) compared the effects of
a proprietary extract of willow bark
(Assalix®, standardised to 15.2% salicin,
i.e. 60 mg salicin per tablet) and a se-
lective COX-2-inhibitor (rofecoxib,
12.5 mg) for low back pain. There was
no significant difference in effective-
ness between the two treatments at
the doses chosen [3]. Willow bark ex-
Background: This is an observational study with a proprietary extract of willow bark (Assalix®)
under conditions of daily practice in Switzerland. The scope of the study was to get a better esti-
mate of the frequency of adverse events (and possibly identify unknown adverse reactions) and
a broader picture of the efficacy. Methods: Any adult patient eligible for treatment with the pro-
prietary extract of willow bark could be admitted to the trial. The study had a duration of 6–8
weeks, with an intermediate control visit after 3–4 weeks. Besides the customary demographic
and anamnestic data, the variables assessed (intent to treat) were pain intensity, impairment of
daily activities and global assessment of efficacy and tolerability. Results: 204 participating physi-
cians treated 877 patients with different types of rheumatologic pain (Females 64.2%, age 58.76
± 15.69 years); 763 patients completed the study. The medical problem had persisted more than
six months in 68% of the cases and 81.2% of the patients had already received another treat-
ment. Additional anti-inflammatory drugs were co-prescribed in 39.3% of cases. The pain score
at admission was 5.32 ± 1.62 (on a scale of 0–9) and at last visit it was 2.51 ± 2.04 (p<0.001);
‘total pain relief’ was reported by 14% of patients. While at admission 0.6% of the patients
reported no impairment of daily activities, at last visit the proportion was 27.4%. Thirty-eight
patients (4.3%) reported a total of 46 adverse events relating predominantly to digestive system
(3.1%) and skin (1.6%). There were no ‘serious’ clinical adverse events. Adverse events were
more frequent in cases receiving additional anti-inflammatory medication. Conclusions: The pro-
prietary extract of willow bark (Assalix®) was well tolerated, with no unexpected adverse events
identified. With the limitations inherent to the study design, it may be concluded that it was mod-
erately effective as an analgesic in the management of dorsopathies, soft tissue disorders,
inflammatory polyarthropathies and arthrosis.
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Schmerzlinderung in der Rheumatologie mit einem Weidenrinden-
Spezialextrakt. Eine offene Studie.
Hintergrund: Bei der vorliegenden Studie handelt es sich um eine Anwendungsbeobachung
unter Praxisbedingungen in der Schweiz, durchgeführt mit einem Weidenrinden-Spezialextrakt
(Assalix®). Ziel der Studie war es, eine bessere Einschätzung zur Häufigkeit von Nebenwirkungen
(und möglicherweise die Identifizierung bisher nicht bekannter Nebenwirkungen) und zur Wirk-
samkeit zur erhalten. Methoden: In die Studie aufgenommen wurden Patienten im
Erwachsenenalter, die aufgrund ihres Beschwerdebildes für eine Behandlung mit dem Extrakt
geeignet waren. Die Studiendauer betrug 6–8 Wochen, wobei eine Kontrolle nach 3–4 Wochen
erfolgte. Neben den üblichen demografischen und anamnestischen Daten wurden die Variablen
(Intent-to-treat) Schmerzintensität, Beeinträchtigung im täglichen Leben sowie globale
Beurteilung von Wirksamkeit und Verträglichkeit erhoben. Ergebnisse: Die 204 teilnehmenden
Ärzte behandelten 877 Patienten mit unterschiedlichen rheumatisch bedingten Schmerzen
(Frauen 64,2%, Alter 58,76 ± 15,69); 763 Patienten konnten die Studie abschliessen. In 68% der
Fälle betrug die Dauer der Beschwerden mehr als 6 Monate und 81,2% der Patienten hatte
bereits eine andere Medikation erhalten. Eine anti-inflammatorische Comedikation erfolgte bei
39,3% der Patienten. Der Schmerz-Score betrug 5,32 ± 1,62 (auf einer Skala von 0–9) zu Studien-
beginn und bei der letzten Konsultation 2,51 ± 2,04 (p<0,001); völlige Schmerzfreiheit wurde von
14% der Patientinnen berichtet. Während zu Studienbeginn lediglich 0,6% der Patienten über
keine Beeinträchtigungen in ihrem täglichen Leben berichteten, waren dies bei der Schlussvisite
27,4%. 38 Patienten (4,3%) berichteten über insgesamt 46 unerwünschte Wirkungen, die vor-
wiegend das Verdauungssystem (3,1%) und die Haut (1,6%) betrafen. “Ernsthafte” Nebenwirkun-
gen wurden nicht beobachtet. Nebenwirkungen traten häufiger unter der anti-inflammatorischen
Comedikation auf. Schlussfolgerungen: Der untersuchte Weidenrindenextrakt (Assalix®) wurde
gut vertragen, unerwartete Nebenwirkungen traten keine auf. Unter Berücksichtigung des
Studiendesigns kann festgestellt werden, dass der Extrakt eine moderat analgetische Wirksam-
keit bei Dorsopathien, Weichteilrheuma, entzündlichen Polyarthropathien und bei Arthrose besitzt.
Schlüsselwörter: Weidenrinde, Rheumatologie, Rückenschmerzen, Anwendungsbeobachtung,
Sicherheit, Analgesie, Pflanzenzubereitung
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* White Willow Bark – Potentially Active
Chemical Constituents: Glycosides (1.5–11%):
salicylates (salicin, salicortin, populin, fragilin,
tremulacin); Tannins (8–20%); Aromatic alde-
hydes and acids: salidroside, vanillin, syringin,
salicylic acid, caffeic and ferulic acids; Salicyl
alcohol (saligenin); Flavonoids.
tract also showed a moderate anal-
gesic effect in osteoarthritis (n=78), as
compared to placebo [4]. These results
were not confirmed with an other pro-
prietary extract of willow bark (n=43)
in an RCT [5] against placebo (n=41)
and against diclofenac (n=43). Only di-
clofenac was superior to placebo in
this trial (WOMAC-Index, SF-36, global
assessment).
The study presented herein is an
open, descriptive, observational case
series study with a proprietary extract
of willow bark (Assalix®) under condi-
tions of daily practice in Switzerland
(“Praxiserfahrungsbericht”). The scope
of such studies [6] is to obtain informa-
tion about prescription modalities, ac-
ceptability, medication compliance, to
get a better estimate of the frequency
of adverse events (and possibly identify
rare hitherto unknown adverse reac-
tions) and to get a broader picture of
the efficacy (e.g. inclusion of sub-
groups not studied in earlier trials). 
Methods
This is an open trial with a proprietary
extract of willow bark (Assalix®); the
approved indications in Switzerland*
are: “Rheumatic troubles such as neck
pain, lower back pain and dorsalgia”.
The study was conducted according to
ethical standards and regulatory re-
quirements at that time in force.
Patient selection and treatment
We enrolled patients from 204 physi-
cians in Switzerland. Any adult patient
eligible for treatment with the propri-
etary extract of willow bark according
to the approved indications could be
admitted to the trial. 
The study duration was 6–8 weeks,
with an intermediate control visit after
3–4 weeks. Besides the customary de-
mographic and anamnestic data in-
cluding concomitant diseases and
treatments, the variables recorded are
shown in table 1. No blood chemistry,
coagulation nor haematology data
were recorded.
Statistics
An intention-to-treat (ITT), last obser-
vation carried forward (LOCF) approach
was used in all appropriate analyses in
all the cases having had at least one
control visit. Missing values were re-
placed by the LOCF method; variables
assessed only once were not replaced
in the analysis. The safety population,
defined as subjects who received at
least one dose of the study drug and for
whom post-dose data were available,
were used in the analysis and evalua-
tion of the safety variables.
Statistical analysis was performed
with WinSTAT® Version 2001.1 for Ex-
cel. The continuous data are presented
as means, standard deviations (SD),
and number of subjects; categorical
data are presented using counts and
percentages. For illustration, final data
are compared with the corresponding
values at baseline. Unless stated other-
wise, values before vs. after treatment
were compared by means of the Stu-
dents-‘t’-test, or the χ2-test for nominal
or ordinal data. In the case of large or
significant differences in the t-Test, a
confirmatory non-parametric analysis
was performed. All P values were two-
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Tab. 1. Variables assessed in the trial
Type of data Variables
Ordinal  Duration of disease (< 3 months, 3–6 months, > 6 months)
 Duration of pain episodes (continuous, recidivating prolonged 
episodes, short bursts)
 Pain triggered by (pain on weight bearing, initial pain, nocturnal pain)
 Impairment of daily activities (absent, mild, evident, important, very
important) 
 Additional analgesic medication
 Global assessments of tolerability and efficacy:
1. vs. previous treatment (much better, better, equal, worse, much 
worse than previous treatment)
2. of current treatment (very good, good, moderate, nihil)
Continuous  Pain intensity absent – unbearable pain (scale with 10 numerical 
boxes)
Admitted
N = 877
Visit 3-4 weeks
N = 802
Visit 6-8 weeks
N = 763
LOCF
N = 876
Withdrawn
N = 75
Withdrawn
N =  39
multiple mentions possible
4Other
4Adverse Event
4Compliance
6Free of pain
23Efficacy insufficient
NCause
multiple mentions possible
5Other
20Adverse Event
4Compliance
17Free of pain
32Efficacy insufficient
NCause
Fig. 1. Study flow.
* Indications in Germany include fever, head-
aches, rheumatism (Rheumatoid arthritis, etc.)
tailed, and P <0.05 was considered sta-
tistically significant. No formal statisti-
cal analysis of safety data was per-
formed. 
Results
The 204 participating physicians treated
877 patients with different types of
rheumatologic pain (Females 64.2%,
males 35.8%, age 58.76 ± 15.69 years);
763 patients completed the study 
(figure 1). The troubles had persisted
more than six months in 68% of the
cases and 81.2% of the patients had al-
ready received another treatment.
Pain was described as ‘continuous’ by
46.4% of the patients while only 16.2%
described pain in ‚short bursts’. In
most cases (76.8%) the pain was trig-
gered by weight bearing. The diseases
of the musculoskeletal system and con-
nective tissue treated with this willow
bark extract are summarized in table 2;
in about two thirds of the cases the
prescription was ‘off-label’ (Swiss ap-
proved labelling). The most common
premedications and additional med-
ications were NSAIDs and COX-2-in-
hibitors (co-prescribed in 39.3% of the
cases; table 3).
The pain score at admission was
5.32 ± 1.62 (on a scale of 0–9) and at
last visit (LOCF) it was 2.51 ± 2.04; that
is, reduced by –2.81 ± 2.11 points
(table 4, p<0.001). Total analgesia was
reached in 123 (14%) of the patients;
they reported ‘total pain relief’ for the
first time after 30.01 ± 18.86 days.
Also the impairment of daily activities
improved markedly; while at admis-
sion only 0.6% of the patients reported
no impairment, at last visit (LOCF) the
proportion had increased to 27.4%
(figure 2). Regarding the mean ratings
of pain or the percentage reporting ‘to-
tal pain relief’ at the end of trial, by
main category of disease, there are no
notorious differences between diag-
noses (table 5). However, arthrosis
fared somewhat worse than the other
diagnoses, a difference which becomes
more evident when restricting the
analysis to patients without additional
medication (table 6). 
Frequently, the more severe cases
received an additional medication. At
baseline, patients receiving additional
anti-inflammatory therapy differed
from those without in that they had a
higher pain score (5.49 ± 1.62 vs. 5.20
± 1.62; p<0.02), more frequent ‘severe’
or ‘very severe’ impairment of daily
activities (39.8% vs. 30.1%; p<0.01),
and enclosed more chronic cases (>6
months, 81.4% vs. 60.9%) and, consis-
tently, more cases with previous treat-
ment (96.5% vs. 71.4%). These differ-
ences in pain score and impairment of
daily activities persisted at the end of
the trial and the global assessment of
efficacy was less favourable in patients
with additional anti-inflammatory ther-
apy (‘good’ or ‘very good’ = 56.8% vs.
75.2%; p<0.01) and fewer patients had
attained ‘total pain relief’ (5.8% vs.
19.4%; p<0.01). For corrected influ-
ence of additional medication on out-
comes, see below: exploratory analysis
(predictors of response).
Compared with the previous treat-
ment, 55.3% of the patients considered
the proprietary extract of willow bark
(Assalix®) to be “better” or “much bet-
ter“ regarding efficacy and 68.1% re-
ported tolerability to have been “bet-
ter” or “much better“. The global as-
sessments of the proprietary extract of
willow bark were “good” or “very
good” for efficacy in 65.8% of the cases
and for tolerability in 92.4% of the
cases (figures 3, 4). 
While 62% of the patients decided to
continue treatment with the propri-
etary extract of willow bark after the
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Tab. 2. Rheumatologic diagnoses, grouped (ICD-10)
ICD-10 Descriptor n %
M05–M14 Inflammatory polyarthropathies 86 9.8
M15–M19 Arthrosis 385 44.0
M40–M54 Dorsopathies (mainly "other dorsopathies") 309 35.3
M60–M79 Soft tissue disorders 94 10.7
M80–M94 Osteopathies and chondropathies 1 0.1
No data 2 0.2
Total 877 100.0
Tab. 4. Mean pain score during the trial
Pain scale 0–9 Mean SD n
Admission 5.32 1.62 876
Week 3–4 3.15 1.87 836
Week 6–8 2.27 1.85 749
LOCF Pain 2.51 2.04 877
Difference
LOCF-T0 –2.81 2.11 876
Tab. 3. Medications before the study and concomitant additional medications (n=number of drugs
prescribed; multiple mentions possible)
Before trial (n / %) Additional (n / %)
NSAID 652 / 74.3 255 / 29.1
COX-2-Inh 230 / 26.2 78 / 8.9
Opioids 93 / 10.6 61 / 7
Corticosteroids 19 / 2.2 11 / 1.3
Benzodiazepines 31 / 3.5 17 / 1.9
Immunosupr. 15 / 1.7 18 / 2.1
Herbal Analg. 9 / 1 7 / 0.8
Other 47 / 5.4 23 / 2.6
No Data 6 / 0.7 1 / 0.1
Medicated 712 / 81.2 345 / 39.3
No medication 165 / 18.8 532 / 60.7
Total 877 / 100 877 / 100
end of the study period, the remaining
patients opted for a discontinuation,
mainly because of insufficient efficacy
(15.2%), absence of pain (11.3%) or
poor tolerability (1.8%). 
Thirty-eight (4.3%) patients reported
a total of 46 adverse events relating
predominantly to the digestive system
(3.1%) and the skin (1.6%). Only ab-
dominal pain (1.1%) and nonvesicular
rash (1%) reached the 1% threshold.
There were no ‘serious’ adverse
events. In 30 cases treatment was dis-
continued, although only 5 patients re-
ported the adverse events as being ‘se-
vere’. The investigators considered the
adverse event as being ‘certainly’ or
‘probably’ treatment-related in 27 cases.
No cases of cross-sensibilisation with
salicylates have been reported [7]. The
detailed adverse events reported dur-
ing the trial, stratified by patients with
or without co-medication (table 7),
show that particularly abdominal pain
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Tab. 5. Mean rating of pain (SD) and % of asymptomatic patients at the end of trial, by main category of disease of the musculoskeletal system
Soft tissue Dorsopathies Arthrosis Inflammatory
disorders polyarthropathies
n = 94 n = 309 n = 384 n = 86
Admission 5.52 (1.63) 5.41 (1.63) 5.21 (1.58) 5.28 (1.68)
Week 3–4 3.14 (2) 3.15 (1.89) 3.07 (1.75) 3.49 (2.1)
Week 6–8 2.5 (2.07) 2.2 (1.78) 2.26 (1.79) 2.32 (1.98)
LOCF 2.67 (2.17) 2.48 (2.04) 2.48 (1.96) 2.55 (2.18)
Difference LOCF-T0 –2.85 (2.15) –2.93 (2.09) –2.73 (2.03) –2.73 (2.49)
% ‘total pain relief’ * 19.1% (11.2, 27%) 14.6% (10.7, 18.5%) 11.5% (8.3, 14.7%) 16.3% (8.5, 24.1%)
% no impairment * 25.5% (16., 34.3%) 31.4% (26.2, 36.6%) 23.4% (19.2, 27.6%) 31.4% (21.6, 41.2%)
* = (95% CI)
none
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severe
very
severe
Last LOCF
Week  3-4
Admission
0
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Fig. 2. Impairment of daily activities at admission, at interim and at last visit.
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Tab. 6. Patients without additional medication, mean rating of pain (SD) and % of asymptomatic patients at the end of trial, by main category of dis-
ease of the musculoskeletal system
Soft tissue Dorsopathies Arthrosis Inflammatory
disorders polyarthropathies
n = 68 n = 182 n = 235 n = 49
Admission 5.49 (1.62) 5.43 (1.71) 5.12 (1.58) 5.29 (1.73)
Week 3-4 3.03 (2.05) 3.16 (1.98) 3.09 (1.73) 3.23 (1.98)
Week 6-8 2.33 (2.06) 2.19 (1.88) 2.37 (1.8) 2.16 (2.08)
LOCF 2.5 (2.15) 2.52 (2.16) 2.56 (1.94) 2.47 (2.29)
Difference LOCF-T0 2.99 (2.27) -2.91 (2.16) -2.56 (1.9) -2.82 (2.69)
% ‘total pain relief’ * 23.5% (13.43, 33.63%) 15.9% (10.63, 21.23%) 10.2% (6.31, 14.11%) 20.4% (9.11, 31.71%)
% no impairment * 29.4% (18.61, 40.21%) 32.4% (25.62, 39.22%) 20.9% (15.65, 26.05%) 36.7% (23.23, 50.23%)
* = (95% CI)
and diarrhoea were more frequent in
patients with co-medication. It should
be remembered that no laboratory
data were recorded in this trial.
Exploratory analysis
Predictors of response
Regarding the outcomes of pain reduc-
tion (Diff. LOCF – T0) and of reduction
of impairment of daily activities in a
stepwise regression model, it was pos-
sible to assess factors which are likely
to influence these outcomes (table 8).
The model included as independent
variables the main diagnostic cate-
gories gender, age, duration of the dis-
ease since diagnosed, duration of the
pain episodes, severity of pain (scale
0–9) and of impairment of daily activi-
ties (scale 0–4), daily dose of willow
bark extract, and whether the patient
had previous treatment or additional
treatment. Pain reduction (Diff. LOCF –
T0) and reduction of impairment of
daily activities, were both favoured by
higher ratings at start, by a recent on-
set of the disease, by the additional ad-
ministration of another analgesic or
anti-inflammatory drug and by having
pain in short episodes or bursts. The
advantage of being younger or male
was not consistent; that is, significant
for one outcome but not the other.
Dose-effect relationship
Regarding the changes in pain assess-
ments and in impairment of activities –
restricted to patients in the two main
diagnostic categories, without co-med-
ication and with an initial pain-score of
5 or higher, the higher dose of 3–4
tablets daily was somewhat more ef-
fective than the lower dose. Only in pa-
tients with arthrosis did the difference
between doses of mean pain reduction
reach the threshold of significance:
Mean pain reduction with 3–4 tablets/
day –3.79 (2.1) points vs. –3.09 (2.13)
score points with 1–2 tablets/day (p=
0.047). In the case of dorsopathies, the
corresponding values were –4.15 (2.22)
vs. –3.5 (2.59) score points, respec-
tively (p = 0.128).
Discussion
The present study with a proprietary
extract of willow bark (Assalix®) con-
firmed the favourable tolerability of
this preparation. Only 4.3% of the pa-
tients reported non-serious adverse
events relating to the digestive system
(3.1%), the skin (1.6%) or non-specific
general symptoms (0.6%). These ad-
verse events were more frequent in
patients receiving additional anti-in-
flammatory medications (5.5% vs. 3.1%
without co-medication). Being a de-
scriptive, observational (case series)
study, it was more likely to require sta-
tistical adjustments because of the po-
tential for larger covariate imbalances
than in randomised trials. From the
point of view of efficacy, soft tissue dis-
orders and dorsopathies fared some-
what better than arthrosis, particularly
regarding ‘total pain relief’ and ab-
sence of impairment of daily activities
at the end of the study. Globally, effi-
cacy is moderate, with 14% of the pa-
tients reporting ‘total pain relief’ for
the first time after one month of treat-
ment. Nevertheless, 55.3% of the pa-
tients considered the proprietary ex-
tract of willow bark (Assalix®) to be
“better” or “much better” than the
previous treatment regarding efficacy.
The global assessments were “good”
or “very good” for efficacy in 65.8% of
the cases and for tolerability in 92.4%
of the cases. The global assessments
correlated well with the changes in
pain rating (Rho = 0.63) and the rating
of impairment of daily activities (Rho =
0.61). The more severe cases received
an additional anti-inflammatory med-
ication which improved significantly
the corrected outcomes in rating of
pain and impairment of daily activities
(regression analysis). Both pain reduc-
tion and improvement of daily activi-
ties were also favoured by higher rat-
ings at start, by a recent onset of the
disease and by having pain in short
episodes or bursts. However, placebo
effects plus disease’s natural history
and regression to the mean can result
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very good, 54.4%
good, 38.0%
moderate, 3.1%
no data, 3.1%
poor, 1.5%
Fig. 4. Global assessment (last visit) of tolerability.
very good, 20.1%
good, 45.7%
moderate, 22.0%
poor, 9.1%
no data, 3.1%
Fig. 3. Global assessment (last visit) of efficacy.
in high rates of good outcomes, which
may be misattributed to specific treat-
ment effects [8,9]. The higher dose of
3–4 tablets daily was somewhat more
effective than the lower recommended
dose of 1–2 tablets daily. While it would
be premature to draw any conclusions
from these findings in view of the lim-
ited significances and the observa-
tional nature of the trial, it may be of
interest as a hypothesis for future trials
with the product. For other propri-
etary ethanolic extracts of willow bark
(Assplant® Robugen) a daily dose of up
to 240 mg salicin is already recom-
mended. The findings are in line with
those of GAGNIER et al. [10] that “there
is moderate evidence that a daily dose
of 240 mg salicin from an extract of
Salix alba reduces pain more than 
either placebo or a daily dose of
120 mg of salicin in the short term for
individuals with acute episodes of
chronic non-specific low-back pain.
One of the problems of observa-
tional studies as the one presented
here is the absence of a placebo con-
trol group. The true causes of improve-
ments in pain after treatment remain
unknown in the absence of indepen-
dently evaluated randomized con-
trolled trials [11]. In patients with
chronic low back pain it has been
shown, for example [12], that high and
moderate levels of psychopathology
are associated with heightened placebo
analgesia (total pain relief 23.5% vs.
7.7% in patients with low psychological
symptomatology). 
Conclusions
In this open observational study, the
proprietary extract of willow bark (As-
salix®) was well tolerated, without new
or serious adverse events identified.
With the limitations inherent to the
study design, it may be concluded that
it was moderately effective as an anal-
gesic in the management of dorso-
pathies (mainly “other dorsopathies”),
soft tissue disorders, inflammatory
polyarthropathies, and arthrosis. A
positive outcome was favoured by a re-
cent onset of the disease, by the addi-
tion of another anti-inflammatory drug
and by having pain in short episodes or
bursts. An increase of the daily dose to
4 tablets is likely to be more effective
than the currently recommended dose
of 2 tablets per day. Adequate RCTs are
needed to confirm this.
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Tab. 8. Predictors of pain reduction and of improvement of daily activities (Diff. LOCF – T0), stepwise regression analysis
Dependent variable: Pain Dependent variable: Daily activities
Independent variable P Pain reduction larger in cases P Activities improved more in cases
Duration of disease <0.001 of recent onset <0.001 of recent onset
Additional treatment <0.001 with additional medication <0.001 with additional medication
Pain at T0 <0.001 with more pain at start <0.001 with more pain at start
Pain episodes =0.001 with pain in short bursts =0.001 with pain in short bursts
Pre-treated ns na =0.004 with pre-treatment
Age ns na =0.049 younger patients
Gender 0.039 males ns na
ns = not significant, na = not analysed
Tab. 7. Adverse events reported during the trial, stratified by patients with or without co-medication
Term With co-medication No co-medication All combined*
n = 345 n = 488 n = 877
Abdominal pain, unspec. 6 (1.7%) 4 (0.8%) 10 (1.1%)
Rash, nonvesicular, unspec. 3 (0.9%) 5 (1%) 9 (1%)
Diarrhoea NOS 4 (1.2%) 1 (0.2%) 5 (0.6%)
Nausea 1 (0.3%) 1 (0.2%) 4 (0.5%)
Constipation, unspec. 4 (1.2%) 0 (0%) 4 (0.4%)
Urticaria, unspec. 1 (0.3%) 2 (0.4%) 3 (0.3%)
Dyspepsia 2 (0.6%) 0 (0%) 2 (0.2%)
Pruritus, NOS 0 (0%) 0 (0%) 2 (0.2%)
Other adverse events (1 diagnosis each) 3 (0.9%) 3 (0.6%) 7 (0.8%)
N adverse events (AE) 24 16 46
N Patients with AE (%) 19 (5.5%) 15 (3.1%) 38 (4.4%)
* = includes cases without data on co-medication
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